With bioinformatics analyses and experiments, overexpression of PSAT1 gene in nasopharyngeal carcinoma (NPC) [33], ovarian cancer [34], gliomas [35], colorectal carcinoma (CRC) [36] and non-small cell lung cancer (NSCLC) [37], was also identified as a potential diagnostic and prognostic biomarker for clinical outcomes prediction. This evidence concerns the gene PSAT1 and non-small cell lung carcinoma.